euglena Co., Ltd. (2931) AI Stock Analysis

1 Followers

euglena Co., Ltd.

(TSE/TYO:2931)

Select Model

Rating:53Neutral

Price Target:JPY 308.00▼(-1.91% Downside)

Action:reiterated

Date:11/08/26

The overall score is constrained by very weak technicals and a negative P/E ratio. The primary support comes from a fundamentally improving financial position, highlighted by strong cash flow generation and a healthier balance sheet, though persistent net losses remain a significant risk.

Positive Factors

Revenue and Operating RecoverySustained revenue expansion alongside a move into operating profitability indicates improving scale and execution. If maintained, this combination can strengthen the company’s ability to fund product development, support distribution growth, and convert its microalgae platform into a more durable earnings base.

Negative Factors

Net Losses and Negative ROEOperating improvement has not yet translated into sustained bottom-line profitability or positive shareholder returns. Continued net losses can constrain internally generated capital, weaken return potential, and leave the company more dependent on further operating gains to establish a durable earnings model.

euglena Co., Ltd. (2931) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 43.80B
Dividend Yield: 0.64%
Average Volume (3M): 661.06K
Price to Earnings (P/E): -245.3
Beta (1Y): 0.51
Revenue Growth: 7.72%
EPS Growth: -1053.09%
Country: Japan
Employees: 793
Sector: Consumer Defensive
Sector Strength: 62
Industry: Household & Personal Products

euglena Co., Ltd. Business Overview & Revenue Model

Company Description

Euglena Co., Ltd. is a Japanese enterprise specializing in the research, development, cultivation, and marketing of microalgae. Its operations are structured around two primary divisions: Healthcare Business and Energy/Environment Business. The compa...

How the Company Makes Money

The company makes money primarily by selling microalgae-derived products and ingredients. Key revenue streams include: (1) Consumer product sales in the health/functional food domain, where Euglena-branded supplements, health foods, and related consu...

euglena Co., Ltd. Financial Statement Overview

Summary

Financial performance is mixed but improving. Revenue growth and a 70% gross margin are strong, and operating profit turned positive. Cash flow is a standout, with operating cash flow doubling to ¥5.2B. However, the company remains unprofitable on a net basis, which tempers the score.

Income Statement

60Neutral

Balance Sheet

70Positive

Cash Flow

80Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	52.32B	50.37B	47.62B	46.48B	44.39B	27.54B
Gross Profit	35.78B	32.06B	30.00B	29.81B	29.05B	16.22B
EBITDA	6.67B	6.47B	3.90B	1.51B	-359.00M	-3.50B
Net Income	-172.00M	-805.00M	-650.00M	-2.65B	-2.67B	-4.03B
Balance Sheet
Total Assets	69.27B	72.33B	73.26B	59.62B	57.27B	61.01B
Cash, Cash Equivalents and Short-Term Investments	17.17B	21.16B	20.63B	15.79B	9.95B	10.19B
Total Debt	23.06B	27.68B	25.92B	25.07B	22.22B	24.91B
Total Liabilities	37.70B	43.80B	41.14B	39.40B	37.92B	40.42B
Stockholders Equity	33.18B	30.96B	31.70B	20.21B	19.35B	20.58B
Cash Flow
Free Cash Flow	0	4.98B	2.23B	345.00M	595.00M	1.18B
Operating Cash Flow	0	5.19B	2.65B	658.00M	924.00M	1.38B
Investing Cash Flow	0	-585.00M	-7.99B	-646.00M	1.23B	-10.34B
Financing Cash Flow	0	-2.43B	-485.00M	5.83B	-2.99B	12.06B

euglena Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price314.00

Price Trends

50DMA335.66Negative

100DMA339.55Negative

200DMA363.06Negative

Market Momentum

MACD-6.69Positive

RSI40.10Neutral

STOCH32.29Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2931, the sentiment is Negative. The current price of 314.00 is below the 20-day moving average (MA) of 324.15, below the 50-day MA of 335.66, and below the 200-day MA of 363.06, indicating a bearish trend. The MACD of -6.69 indicates Positive momentum. The RSI at 40.10 is Neutral, neither overbought nor oversold. The STOCH value of 32.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2931.

euglena Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (62)

Financial Indicators

JP:2931 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:4452	73Outperform	JPY 3.62T	25.94	12.88%	1.93%	6.31%	18.40%
JP:4911	68Neutral	JPY 1.68T	35.23	―	1.19%	5.79%	―
JP:4922	67Neutral	JPY 341.67B	26.81	4.51%	2.34%	4.49%	70.29%
JP:4527	65Neutral	JPY 567.75B	16.69	10.90%	2.04%	7.39%	-7.02%
Sector *	62Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
JP:4967	61Neutral	JPY 523.29B	114.40	2.19%	1.49%	2.46%	-60.25%
JP:2931	53Neutral	JPY 43.80B	-245.31	―	0.64%	7.72%	-1053.09%

* Consumer Defensive Sector Average

Performance Comparison

JP:2931 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:2931	euglena Co., Ltd.	314.00	-122.00	-27.98%
JP:4452	Kao Corp	4006.00	833.72	26.28%
JP:4967	Kobayashi Pharmaceutical Co	7056.00	1864.52	35.92%
JP:4922	Kose Corporation	5989.00	1042.90	21.09%
JP:4527	Rohto Pharmaceutical Co	2445.50	46.40	1.93%
JP:4911	Shiseido Company,Limited	4205.00	1830.10	77.06%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026

euglena Co., Ltd. AI Stock Analysis